Sarepta Therapeutics (SRPT) Other financing activities (2013 - 2026)

Sarepta Therapeutics' Other financing activities history runs 12 years deep, the most recent figure standing at $241000.0 for Q1 2026.

• On a quarterly basis, Other financing activities fell 98.46% year-over-year to $241000.0 in Q1 2026; TTM through Mar 2026 was $3.3 million, a 95.53% decrease from a year earlier, with the FY2025 full-year figure at $18.7 million, down 76.48% from the prior year.
• Other financing activities retreated to $241000.0 in Q1 2026 per SRPT's latest filing, from $308000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $39.9 million in Q2 2024 and bottomed at $241000.0 in Q1 2026.
• The 5-year median for Other financing activities is $5.9 million (2023), against an average of $10.6 million.
• Across the five-year window, Other financing activities jumped 1628.91% in 2023 and sank 98.46% in 2026, its largest moves.
• Year by year, Other financing activities stood at $11.3 million in 2022, then plunged by 82.81% to $1.9 million in 2023, then jumped by 90.94% to $3.7 million in 2024, then slumped by 91.7% to $308000.0 in 2025, then fell by 21.75% to $241000.0 in 2026.
• Per Business Quant, the three latest SRPT Other financing activities figures stand at $241000.0 (Q1 2026), $308000.0 (Q4 2025), and $1.2 million (Q3 2025).